Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Memory Impairment - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Memory Impairment - Pipeline Review, H1 2015', provides an overview of the Memory Impairment's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Memory Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Memory Impairment - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Memory Impairment Overview 8 Therapeutics Development 9 Pipeline Products for Memory Impairment - Overview 9 Pipeline Products for Memory Impairment - Comparative Analysis 10 Memory Impairment - Therapeutics under Development by Companies 11 Memory Impairment - Therapeutics under Investigation by Universities/Institutes 12 Memory Impairment - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Memory Impairment - Products under Development by Companies 15 Memory Impairment - Products under Investigation by Universities/Institutes 17 Memory Impairment - Companies Involved in Therapeutics Development 18 Calico LLC 18 Dart NeuroScience LLC 19 M et P Pharma AG 20 Neuren Pharmaceuticals Limited 21 Omeros Corporation 22 Pharnext SAS 23 Sunovion Pharmaceuticals Inc. 24 Takeda Pharmaceutical Company Limited 25 Memory Impairment - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 2-PMPA - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AC-253 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 dehydroevodiamine hydrochloride - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Drug for Memory Impairment - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 HT-0712 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 HT-3951 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NNZ-2591 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 P7-C3A20 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 pregnenolone succinate - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PXT-864 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 roflumilast - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecule 1 to Inhibit GlyT-1 for Memory Impairment - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecule 1 to Inhibit PDE4 for Memory Impairment - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecule 2 to Inhibit Glyt-1 for Memory Impairment - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule 2 to Inhibit PDE4 for Memory Impairment - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecule to Inhibit MAO-B for Memory Impairment - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecules to Activate Carbonic Anhydrase for Learning and Memory Impairment - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecules to Activate PKC for CNS and Oncology - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Small Molecules to Antagonize GALR3 for Memory Impairment - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Stem Cell Therapy for Memory Impairment and Brain Diseases - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Memory Impairment - Recent Pipeline Updates 64 Memory Impairment - Dormant Projects 67 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables Number of Products under Development for Memory Impairment, H1 2015 9 Number of Products under Development for Memory Impairment - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Development by Companies, H1 2015 (Contd..1) 16 Products under Investigation by Universities/Institutes, H1 2015 17 Memory Impairment - Pipeline by Calico LLC, H1 2015 18 Memory Impairment - Pipeline by Dart NeuroScience LLC, H1 2015 19 Memory Impairment - Pipeline by M et P Pharma AG, H1 2015 20 Memory Impairment - Pipeline by Neuren Pharmaceuticals Limited, H1 2015 21 Memory Impairment - Pipeline by Omeros Corporation, H1 2015 22 Memory Impairment - Pipeline by Pharnext SAS, H1 2015 23 Memory Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 24 Memory Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Number of Products by Stage and Target, H1 2015 28 Number of Products by Stage and Mechanism of Action, H1 2015 30 Number of Products by Stage and Route of Administration, H1 2015 32 Number of Products by Stage and Molecule Type, H1 2015 34 Memory Impairment Therapeutics - Recent Pipeline Updates, H1 2015 64 Memory Impairment - Dormant Projects, H1 2015 67 Memory Impairment - Dormant Projects (Contd..1), H1 2015 68
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
